No Data
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
China to Lift Fiscal Spending to Boost Economy
Asia-Pacific Markets Mixed as China's Key Economic Meeting Kicks Off; Eyes on U.S. CPI Report
Reported Earlier, BeiGene Highlights Long-Term BRUKINSA Efficacy And Pipeline Innovations For CLL At ASH 2024
Asia Markets Surge, Defied Selloff on Wall Street on China's Economic Policy Shift to Spur Growth
0.15 billion! Wuxi AppTec invested in a French VC, adding to the European biomedical market.
① Wuxi Apptec plans to invest in the "Jeito II S.L.P." fund, with a total target scale not exceeding 1.2 billion euros, and the fund is expected to invest in 14-17 medical innovative startups. ② Previously, Wuxi Apptec planned to invest 10 million euros in another well-known biotechnology investment institution in Europe, focusing on early-stage biomedical companies in Europe.